Month: May 2024

HEAWELL AI’s Clinical Co-Pilot technology participated in recently published evidence showing the integration of a highly accurate machine model for Chronic Kidney Disease (“CKD”) progression when paired with Electronic Health Record (“EHR”) linked clinical decision support, improves guideline-recommended testing in patients with CKD. HEALWELL’s subsidiary Khure Health (“Khure”) co-authored an abstract that was published this month in the American Journal of Kidney Diseases, providing evidence of Khure’s Clinical Co-Pilot’s utility to support improved CKD patient care by US Nephrologists. CKD is a major health problem affecting approximately one seventh of the population in North America. In Canada alone, the economic burden of chronic and end-stage kidney disease costs the national healthcare system more than $40 billion per year. WELL...

IDEX Biometrics ASA held its annual general meeting on 16 May 2024. 95.3 million shares or 34% of the capital was represented at the meeting. All resolutions were passed as proposed by the board and nomination committee. The following board was elected at the meeting:Chair: Morten OpstadBoard members: Annika Olsson and Adriana Saitta. The minutes of the meeting will be available at the company’s web site, www.idexbiometrics.com, in due course. For further information contact: Marianne Bøe, Head of investor relations  E-mail: marianne.boe@idexbiometrics.com Tel: + 47 9180 0186  About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and...

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR) – – Across all vepdegestrant dose groups, circulating tumor DNA analyses showed marked reduction in tumor fraction after one treatment cycle, regardless of ESR1 gene mutation status; at the 200 mg vepdegestrant dose, robust on-treatment decreases in mutant ESR1 circulating tumor DNA were sustained through multiple treatment cycles – NEW HAVEN, Conn. and NEW YORK, May 16, 2024...

Kering – Statement Number of Shares and voting rights – 15.05.2024 KeringSociété anonyme with a share capital of €493,683,112Head office: 40, rue de Sèvres – 75007 PARIS552 075 020 RCS PARIS May 16, 2024 Monthly statementon the total number of shares and voting rights(articles L.233-8 of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)Date     Total number ofshares   Total number of voting rightstheoretical 1 exercisable 2May 15, 2024 123,420,778 176,619,961 175,786,0941 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulation). 2 Excluding treasury shares stripped of voting rights.AttachmentKering – Statement...